BPH: Epidemiology and Comorbidities

The document discussed the prevalence of benign prostatic hyperplasia (BPH), noting that it affected about 25% of men in their 50s, 33% in their 60s, and 50% of men aged 80 or older. BPH often co-occurred with age-related conditions like cardiovascular disease, hypertension, and erectile dysfunction. Treatments for BPH included alpha1-selective adrenergic receptor antagonists and 5-alpha-reductase inhibitors, which were effective, particularly in combination for men with larger prostates. However, the choice of treatment needed to consider the side-effect profiles and their potential impact on existing comorbidities.